

01

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/09/833,196

DATE: 05/21/2001  
TIME: 12:14:40

Input Set : N:\CrF3\04272001\I833196.raw  
Output Set: N:\CRF3\05212001\I833196.raw

ENTERED

1 <110> APPLICANT: Abbott Laboratories  
2 Henkin, Jack  
3 Haviv, Fortuna  
4 Bradley, Michael F.  
5 Kalvin, Douglas M.  
6 Schneider, Andrew J.  
7 <120> TITLE OF INVENTION: PEPTIDE ANTIANGIOGENIC DRUGS  
8 <130> FILE REFERENCE: 6356.US.P4  
9 <140> CURRENT APPLICATION NUMBER: US/09/833,196  
10 <141> CURRENT FILING DATE: 2001-04-11  
11 <150> PRIOR APPLICATION NUMBER: US 09/316,888  
12 <151> PRIOR FILING DATE: 1999-05-21  
13 <150> PRIOR APPLICATION NUMBER: US 60/126,546  
14 <151> PRIOR FILING DATE: 1999-03-26  
15 <150> PRIOR APPLICATION NUMBER: US 60/086,536  
16 <151> PRIOR FILING DATE: 1998-05-22  
17 <160> NUMBER OF SEQ ID NOS: 6  
18 <170> SOFTWARE: FastSEQ for Windows Version 4.0  
20 <210> SEQ ID NO: 1  
21 <211> LENGTH: 10  
22 <212> TYPE: PRT  
23 <213> ORGANISM: Artificial Sequence  
24 <220> FEATURE:  
25 <223> OTHER INFORMATION: Antiangiogenetic Peptide  
26 <221> NAME/KEY: VARIANT  
27 <222> LOCATION: (1)...(1)  
28 <223> OTHER INFORMATION: Xaa = Ala, Asn, Cit, Gln, Glu, NetGly, Met,  
29 N-methylalanyl, Pro, pyro-Glu, Sar, Ser, or Thr at  
30 position 1  
31 <221> NAME/KEY: VARIANT  
32 <222> LOCATION: (2)...(2)  
33 <223> OTHER INFORMATION: Xaa = Ala, Asn, Asp, Gln, Glu, Leu, Met, Phe, Pro,  
34 or Ser at position 2  
35 <221> NAME/KEY: VARIANT  
36 <222> LOCATION: (3)...(3)  
37 <223> OTHER INFORMATION: Xaa = Ala, Asn, Cit, Cha, Chg, Gln, Glu, Gly, Ile,  
38 Leu, Met, Nva, Phe, Ser, tButylgly, Thr, Val, Pen,  
39 or Cys at position 3  
40 <221> NAME/KEY: VARIANT  
41 <222> LOCATION: (4)...(4)  
42 <223> OTHER INFORMATION: Xaa = alloIle, Gly, Ile, Pro, or dehydroleu at  
43 position 4  
44 <221> NAME/KEY: VARIANT  
45 <222> LOCATION: (5)...(5)  
46 <223> OTHER INFORMATION: Xaa = Ala, 3-Pal, 1-Nal, 2-Nal, allo-threonyl,  
47 allylgly, Gln, Gly, His, Hser, Ile, Lys(Ac), Met,  
48 Nva, Octylgly, Orn, Phe(4-CH2OH), Pro, Ser, Thr,

LAST AVAILABLE COPY

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/833,196

DATE: 05/21/2001

TIME: 12:14:40

Input Set: N:\Crf3\04272001\I833196.raw  
 Output Set: N:\CRF3\05212001\I833196.raw

49 Trp, Tyr, Pen, or Cys at position 5  
 50 <221> NAME/KEY: VARIANT  
 51 <222> LOCATION: (6)...(6)  
 52 <223> OTHER INFORMATION: Xaa = Ala, 1-Nal, 2-Nal, 3-Pal, Abu, allylgly,  
 53 Arg, Asn, Asp, Cit, Cha, Gln, Glu, Gly, His,  
 54 Homoala, Hle, Hser, Ile, Leu, Lys(Ac), Lys(Isp),  
 55 at position 6  
 56 <221> NAME/KEY: VARIANT  
 57 <222> LOCATION: (6)...(6)  
 58 <223> OTHER INFORMATION: 6 Cont'd:  
 59 Xaa = Met(O2), Met(O), Met, Nor, Nva, Octylgly,  
 60 Phe, Phe(4-CONH2), Propargylgly, Ser, Thr, Trp,  
 61 Tyr, Val, Pen, or Cys at position 6  
 62 <221> NAME/KEY: VARIANT  
 63 <222> LOCATION: (7)...(7)  
 64 <223> OTHER INFORMATION: Xaa = Ala, Allylgly, Asn, Cit, Chg, Gln, Gly,  
 65 Hser, Ile, alleile, Leu, Lys(Ac), Met, 1-Nal,  
 66 2-Nal, Nva, Phe, Pro, Ser, tButylgly, Trp, Tyr,  
 67 Val, Pen, or Cys at position 7  
 68 <221> NAME/KEY: VARIANT  
 69 <222> LOCATION: (8)...(8)  
 70 <223> OTHER INFORMATION: Xaa = Aminopyrimidinobutanoyl, Ala(3-guanidino),  
 71 Ala(3-pyrrolidinylamidino), Ala[4-Pip(N-amidino)],  
 72 Arg, arginyl(NGNG'diethyl), Cit, Cha(4-NIsp),  
 73 Gly[4-pip(N-amido)], at position 8  
 74 <221> NAME/KEY: VARIANT  
 75 <222> LOCATION: (8)...(8)  
 76 <223> OTHER INFORMATION: 8 Cont'd:  
 77 Xaa = His, Harg, Lys, Lys(Ile), Lys(Nic), Norarg,  
 78 Orn(Isp), Orn(Nic), Orn(2-imidazo),  
 79 Phe(4-CH2NIsp), Phe(4-guanidino), or Phe(4-NIsp)  
 W--> 80 at position 8  
 81 <221> NAME/KEY: VARIANT  
 82 <222> LOCATION: (9)...(9)  
 83 <223> OTHER INFORMATION: Xaa = Abu, Aib, homoprolyl, hydroxyprolyl, Ile,  
 84 Leu, Phe, Pro, Ser, tButylgly, Tic, Thr, or Val at  
 85 position 9.  
 86 <221> NAME/KEY: VARIANT  
 87 <222> LOCATION: (10)...(10)  
 88 <223> OTHER INFORMATION: Xaa = azaglycylamide, glycylamide,  
 89 glycylethylamide, sarcosylamide, serylamide at  
 90 position 10  
 91 <400> SEQUENCE: 1  
 W--> 92 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
 93 1 5 10  
 95 <210> SEQ ID NO: 2  
 96 <211> LENGTH: 9  
 97 <212> TYPE: PRT  
 98 <213> ORGANISM: Artificial Sequence

BEST AVAILABLE COPY

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/09/833,196

DATE: 05/21/2001  
TIME: 12:14:40

Input Set : N:\Crf3\04272001\I833196.raw  
Output Set: N:\CRF3\05212001\I833196.raw

## 99 &lt;220&gt; FEATURE:

100 <223> OTHER INFORMATION: Antiangiogenetic peptide  
101 <221> NAME/KEY: VARIANT  
102 <222> LOCATION: (1)...(1)  
103 <223> OTHER INFORMATION: Xaa = sarcosyl at position 1  
104 <221> NAME/KEY: VARIANT  
105 <222> LOCATION: (6)...(6)  
106 <223> OTHER INFORMATION: Xaa = norvaline at position 6  
107 <400> SEQUENCE: 2

W--> 108 Xaa Gly Val Ile Thr Xaa Ile Arg Pro

109 1 5

111 <210> SEQ ID NO: 3  
112 <211> LENGTH: 9  
113 <212> TYPE: PRT  
114 <213> ORGANISM: Artificial Sequence  
115 <220> FEATURE:  
116 <223> OTHER INFORMATION: Antiangiogenetic peptide  
117 <221> NAME/KEY: VARIANT  
118 <222> LOCATION: (1)...(1)  
119 <223> OTHER INFORMATION: Xaa = sarcosyl at position 1  
120 <221> NAME/KEY: VARIANT  
121 <222> LOCATION: (6)...(6)  
122 <223> OTHER INFORMATION: Xaa = norvaline at position 6  
123 <400> SEQUENCE: 3

W--> 124 Xaa Gly Val Gly Thr Xaa Ile Arg Pro

125 1 5

127 <210> SEQ ID NO: 4  
128 <211> LENGTH: 9  
129 <212> TYPE: PRT  
130 <213> ORGANISM: Artificial Sequence  
131 <220> FEATURE:  
132 <223> OTHER INFORMATION: Antiangiogenetic peptide  
133 <221> NAME/KEY: VARIANT  
134 <222> LOCATION: (1)...(1)  
135 <223> OTHER INFORMATION: Xaa = sarcosyl at position 1  
136 <221> NAME/KEY: VARIANT  
137 <222> LOCATION: (4)...(4)  
138 <223> OTHER INFORMATION: Xaa = allo-isoleucyl at position 4  
139 <221> NAME/KEY: VARIANT  
140 <222> LOCATION: (6)...(6)  
141 <223> OTHER INFORMATION: Xaa = norvaline at position 6  
142 <400> SEQUENCE: 4

W--> 143 Xaa Gly Val Xaa Thr Xaa Ile Arg Pro

144 1 5

146 <210> SEQ ID NO: 5  
147 <211> LENGTH: 9  
148 <212> TYPE: PRT  
149 <213> ORGANISM: Artificial Sequence  
150 <220> FEATURE:

REST AVAILABLE COPY

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/09/833,196

DATE: 05/21/2001  
TIME: 12:14:40

Input Set : N:\Crf3\04272001\I833196.raw  
Output Set: N:\CRF3\05212001\I833196.raw

151 <223> OTHER INFORMATION: Antiangiogenetic peptide  
 152 <221> NAME/KEY: VARIANT  
 153 <222> LOCATION: (1)...(1)  
 154 <223> OTHER INFORMATION: Xaa = sarcosyl at position 1  
 155 <221> NAME/KEY: VARIANT  
 156 <222> LOCATION: (4)...(4)  
 157 <223> OTHER INFORMATION: Xaa = dehydroleucyl at position 4  
 158 <221> NAME/KEY: VARIANT  
 159 <222> LOCATION: (6)...(6)  
 160 <223> OTHER INFORMATION: Xaa = norvaline at position 6  
 161 <400> SEQUENCE: 5  
 W--> 162 Xaa Gly Val Xaa Thr Xaa Ile Arg Pro  
 163 1 5  
 165 <210> SEQ ID NO: 6  
 166 <211> LENGTH: 11  
 167 <212> TYPE: PRT  
 168 <213> ORGANISM: Artificial Sequence  
 169 <220> FEATURE:  
 170 <223> OTHER INFORMATION: Antangiogenetic Peptide  
 171 <221> NAME/KEY: VARIANT  
 172 <222> LOCATION: (1)...(1)  
 173 <223> OTHER INFORMATION: Xaa = R-(CH<sub>2</sub>)<sub>n</sub>-C(O)- where R is N-acetylamino at  
 174 position 1  
 175 <221> NAME/KEY: VARIANT  
 176 <222> LOCATION: (2)...(2)  
 177 <223> OTHER INFORMATION: Xaa = Sar at position 2  
 178 <221> NAME/KEY: VARIANT  
 179 <222> LOCATION: (5)...(5)  
 180 <223> OTHER INFORMATION: Xaa = AlloIle, dehydroleu, Gly, Ile or Pro at  
 181 position 5  
 182 <221> NAME/KEY: VARIANT  
 183 <222> LOCATION: (6)...(6)  
 184 <223> OTHER INFORMATION: Xaa = Ala, 3-Pal, 1-Nal, 2-Nal, allo-threonyl,  
 185 allylgly, Gln, Gly, His, Hser, Ile, Lys(Ac), Met,  
 186 Nva, Octylgly, Orn, Phe(3-CH<sub>2</sub>OH), Pro, Ser, Thr,  
 187 Trp, Tyr, Pen or Cys at position 6  
 188 <221> NAME/KEY: VARIANT  
 189 <222> LOCATION: (7)...(7)  
 190 <223> OTHER INFORMATION: Xaa = Ala, 1-Nal, 2-Nal, 3-Pal, Abu, allylgly,  
 191 Arg, Asn, Asp, Cit, Cha, Gln, Glu, Gly, His,  
 192 Homoala, Hle, Hser, Ile, Leu, Lys(Ac), Lys(Isp),  
 193 at position 7  
 194 <221> NAME/KEY: VARIANT  
 195 <222> LOCATION: (7)...(7)  
 196 <223> OTHER INFORMATION: 7 Con'td:  
 197 Xaa = Met(O<sub>2</sub>), Met(O), Met, Nor, Nva, Octygly,  
 198 Phe, Phe(4-CONH<sub>2</sub>), Proparglygly, Ser, Thr, Trp,  
 199 Tyr, Val, Pen, or Cys at position 7  
 200 <221> NAME/KEY: VARIANT

REST AVAILABLE COPY

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/833,196

DATE: 05/21/2001

TIME: 12:14:40

Input Set : N:\Crf3\04272001\I833196.raw  
Output Set: N:\CRF3\05212001\I833196.raw

201 &lt;222&gt; LOCATION: (11)...(11)

202 &lt;223&gt; OTHER INFORMATION: Xaa = Azaglycylamide, glycylamide,

203 glycylethylamide, sarcosylamide, serylamide at

204 position 11

205 &lt;400&gt; SEQUENCE: 6

W--&gt; 206 Xaa Xaa Gly Val Xaa Xaa Xaa Ile Arg Pro Xaa

207 1 5 10

BEST AVAILABLE COPY

VERIFICATION SUMMARY  
PATENT APPLICATION: US/09/833,196

DATE: 05/21/2001  
TIME: 12:14:41

Input Set : N:\Crf3\04272001\I833196.raw  
Output Set: N:\CRF3\05212001\I833196.raw

L:80 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:92 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1  
L:108 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2  
L:124 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3  
L:143 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4  
L:162 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5  
L:206 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6

BEST AVAILABLE COPY